Two research teams have developed models for classifying the clinical outcomes of patients with nonsmall-cell lung cancer (NSCLC) using mass spectrometry techniques . Currently, clinicians do not have adequate methods for determining which patients will benefit from treatment with certain drugs. The new models could help physicians decide who will benefit from certain treatment options.
The studies are published in the June 6 Journal of the National Cancer Institute. In one study, an international team led by David Carbone, M.D., Ph.D., of the Vanderbilt-Ingram Cancer Center in Nashville, developed an algorithm to predict the outcomes of NSCLC patients treated with the drugs gefitinib and erlotinib, two tyrosine kinase inhibitors. The algorithm places patients into categories indicating good or poor survival before treatment with one of the drugs and is based on the pattern of a group of proteins in the patients blood serum.
The authors developed the algorithm on a group of patients with known outcomes then tested it on pretreatment serum for independent validation and control groups. Patients who were predicted to have good outcomes survived for a median of 306 days, while those in the poor group survived a median of 107 days.
In the clinical development of biomarkers for the individualization of therapy, it is important to distinguish between those who will benefit from an intervention from those independent of the planned intervention. Biomarkers predictive for survival benefit from an intervention are much more useful for guiding managementthe authors said.Use of (Protein)signature will reduce rates of both overtreatment and undertreatment and improve survival for NSCLC patients, the authors added.
In the second study, Kiyoshi Yanagisawa, M.D., Ph.D., of Nagoya University in Japan, and colleagues analyzed protein patterns in NSCLC tumor tissue and normal lung tissue. The researchers identified a pattern th
at was associated with increased survival among NSCLC patients and may distinguish patients with poor prognosis from those with good prognosis. They also tested their model on independent validation and control groups. Related medicine news :1
. Clinical trials need to be more frank2
. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses 3
. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics4
. Clinical Comparisons Between ADHD Drugs Are Less5
. A Novel System For Clinical Banking Of Umbilical Cord Blood 6
. Clinical Renal Trails Do Not Have Sufficient Women Participants7
. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment8
. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand9
. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients10
. Cancer Clinical Research in India11
. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care